Subscribe to RSS
Influence of mirtazapine on salivary cortisol in depressed patients
In the present study, the impact of mirtazapine treatment on salivary cortisol secretion was investigated in 12 patients (4 men, 8 women) suffering from major depression according to DSM-IV criteria. Patients were treated with mirtazapine for 3 weeks receiving 15mg mirtazapine on day 0; 30mg mirtazapine on day 1; and 45mg mirtazapine per day from day 2 up to the end of the study (day 21). Response to mirtazapine treatment was defined by a reduction of at least 50% in the Hamilton Rating Scale for Depression after 3 weeks of therapy. Salivary cortisol concentrations were measured before treatment (day -1), at the beginning of treatment (day 0), after 1 week (day 7) and after 3 weeks (day 21) of treatment with mirtazapine. Saliva samples were collected hourly from 0800 a.m. up to 0800 p.m. There was a significant reduction of cortisol concentrations already after one day of mirtazapine treatment which was comparable in responders and non-responders. In addition to new pharmacological approaches such as CRH1 receptor antagonists, mirtazapine therefore appears to be an effective strategy to decrease hypercortisolism and restore HPA system dysregulation in depression.